Clinical Trial Update: Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating alemtuzumab with or without methotrexate and mercaptopurine for relapsed acute lymphoblastic leukemia in young patients has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• METHOTREXATE (METHOTREXATE)
• Mercaptopurine (Mercaptopurine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED